依杜沙班(DU-176B，商號Savaysa，Lixiana)是一種口服抗凝藥物，作為直接因子XA抑制劑。它是由日本三橋大一開發(fā)并于2011年7月批準(zhǔn)用于預(yù)防下肢骨科手術(shù)后靜脈血栓栓塞（VTE）。FDA也于2015年1月批準(zhǔn)了預(yù)防卒中和非中樞神經(jīng)系統(tǒng)全身栓塞的方法。
Cyclohex-3-enecarboxylic acid
tert-Butyl 2-amino-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate
(R)-Cyclohex-3-enecarboxylic acid
tert-Butyl 2-bromo-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate
tert-Butyl ((1R,2S,5S)-2-(2-((5-chloropyridin-2-yl)amino)-2-oxoacetamido)-5-(dimethylcarbamoyl)cyclohexyl)carbamate
Ethyl 3-bromo-2-oxopropanoate
tert-Butyl ((1R,2S,5S)-2-amino-5-(dimethylcarbamoyl)cyclohexyl)carbamate
tert-Butyl (3-mercaptopyridin-4-yl)carbamate
2-Bromo-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine
Methyltriphenylphosphonium bromide
N1-(5-Chloropyridin-2-yl)-N2-((1S,2R,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamide 4-methylbenzenesulfonate hydrate
trans-3-Phenylacrylamide
4-(Boc-Amino)pyridine
5-tert-Butyl 2-methyl 6,7-dihydrooxazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate
N-((1R,2S,5S)-2-Amino-5-(dimethylcarbamoyl)cyclohexyl)-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide
5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine
(1S,3S,6R)-Ethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate
(1S,3R,4S)-Ethyl 4-amino-3-((tert-butoxycarbonyl)amino)cyclohexanecarboxylate
2-Bromo-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine
